Presentatie - vzw farmaka asbl

More documents

Recommendations

Info

CABG vs PTCA Bravata. Systematic review: The comparative effectiveness of PCI and CABG. Ann Intern Med 2007;147:703-16 Design N/n Population Sd Interventions Outcomes Results MA N=23, n=5019 RCT DATA Survival within 30 d -98.9% (PCI) vs 98.2% -Coronary artery disease -40% previous MI -Few had heart failure 6 m to 13y -PCI with or without stent -CABG -Only 1 trial used drugeluting stent Procedure related stroke Mortality at 1y Mortality at 5y Angina relief at 1 to 5 y Repeated revascularization -ARD=0.2% (95%95%CI –0.3 to 0.6%) -1.2% % (CABG) vs 0.6% -ARD= 0.6% (95%95%CI 0.2 to 1%) -96.4 % (CABG) vs 96.5% ; NS -90.7 % (CABG) vs 89.7% ; NS -At 1 y: 84 % (CABG) vs 75% -At 5 y: 84 % (CABG) vs 79% ARD ranged from 5% to 8% in favour of CABG; p
- CABG vs PTCA - • CABG: meer CVA’s gelinkt aan procedure • Mortaliteit en AMI: geen verschil • CABG: minder angor • Minder revascularisaties met CABG (maar quasi geen studies met DES) Bravata. Ann Intern Med 2007;147:703-16 www.<strong>farmaka</strong>.be Project Farmaka
Page 1 and 2:
Projekt Farmaka vzw Centrum voor on
Page 3 and 4:
Hoe? 1. Van een klinisch probleem n
Page 5 and 6:
Aanpak van stabiele angor www.farma
Page 7 and 8:
Definitie en epidemiologie www.farm
Page 9 and 10:
Natuurlijk verloop www.farmaka.be P
Page 11 and 12:
Doelstelling van de behandeling www
Page 13 and 14:
Acute behandeling www.farmaka.be Pr
Page 15 and 16: Anti-anginosa (onderhoudsbehandelin
Page 17 and 18: ANTIANGINOSA (niet in België) - we
Page 19 and 20: β-blokkers Niet-selectieve β-blok
Page 21: NITRATEN Sublinguaal Posologie Isos
Page 24 and 25: β-blokkers 17.Pepine. The atenolol
Page 26 and 27: β-blokkers Preserved ventricular f
Page 28 and 29: β-blokkers Helfand 2007 www.farmak
Page 30 and 31: - β-blokkers - • Mortaliteit en
Page 32 and 33: Calcium-antagonisten Gami P. Second
Page 34 and 35: • Werkzaam op angor - Calciumanta
Page 36 and 37: Nitraten 25.Heidenreich. JAMA 1999;
Page 38 and 39: - Molsidomine - • Werkzaamheid op
Page 40 and 41: - Trimetazidine, ranolazine, nicora
Page 42 and 43: - Combinaties en werkzaamheid angor
Page 44 and 45: Anti-anginosa - ongewenste effecten
Page 50 and 51: Invasieve behandeling www.farmaka.b
Page 52 and 53: - Aanvullende medicatie bij PCI -
Page 54 and 55: www.farmaka.be Project Farmaka
Page 56 and 57: - Terminologie invasieve ingrepen -
Page 58 and 59: PTCA vs enkel medicatie 53.Borzak.
Page 60 and 61: - PTCA vs enkel medicatie - • Bej
Page 62 and 63: - CABG vs enkel medicatie - • ↓
Page 64: -Stents - Bedoeling stents en DES:
Page 69 and 70: Onderhoudsbehandeling Globale CV pr
Page 71 and 72: Rookstop Gami P. Secondary preventi
Page 73 and 74: Mediterraan dieet 1.Gami P. Seconda
Page 75 and 76: Oefentherapie 77. Gami P. Secondary
Page 77 and 78: - Oefentherapie - • Vs “usual t
Page 79 and 80: - Stressmanagement - • Mogelijk
Page 81 and 82: - β-blokkers - Zie hoger www.farma
Page 83 and 84: Anti-aggregantia - ASA Gami P. Seco
Page 85 and 86: Consensusvergadering angor 2006. Di
Page 87 and 88: Anti-aggregantia - Ticlopidine en
Page 89 and 90: ACE-inhibitoren • Bij hoogrisicop
Page 91 and 92: - Sartanen - • Ramipril vs telmis
Page 93 and 94: -Statines - • ↓ mortaliteit en
Page 95 and 96: - Kernboodschappen - Patiënt met s
Page 97 and 98: - Symptomatische behandeling - •
show all

Presentatie - vzw farmaka asbl

Create successful ePaper yourself

Delete template?

Save as template?